`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`AZURITY PHARMACEUTICALS, INC.,
`
`
`Plaintiff,
`
`
`
`v.
`
`
`BIONPHARMA INC. et al.,
`
`
`Defendants.
`
`
`
`
`Civil Action
`
`No. 21-cv-1286
`
`
`
`
`
`
`
`ORDER
`
`AND NOW, this 13th day of July, 2023 upon consideration of letters filed by both parties
`
`respecting a discovery dispute (ECF Nos. 358, 359, 380), and following an on-the-record phone
`
`conference on July 13, 2023, it is hereby ORDERED that Bionpharma may obtain Rule 30(b)(6)
`
`deposition testimony from Azurity regarding the specification and prosecution history of the
`
`patents-in-suit, with the following limitations:
`
`1.
`
`Questions about documents that are also part of the specification or prosecution
`
`history of the “First Wave” patents (U.S. Patent Nos. 9,669,008, 9,808,442, 10,039,745, and
`
`10,154,987) must relate to Bionpharma’s defenses in this case that the patents-in-suit are invalid
`
`for inadequate written description or lack of enablement.
`
`2.
`
`3.
`
`Bionpharma shall not ask the witness to provide legal conclusions.
`
`So as to avoid repetitiousness, counsel for Bionpharma shall avoid asking questions
`
`of the Rule 30(b)(6) witness regarding topics that were previously covered in the “First Wave”
`
`lawsuits (Nos. 18-1962 and 19-1067). The parties are instructed to interpret “topics” of inquiry
`
`reasonably and flexibly to permit new questions about “First Wave” materials without burdening
`
`the witness with repetitious testimony.
`
`1
`
`
`
`Case 1:21-cv-01286-MSG Document 362 Filed 07/13/23 Page 2 of 2 PageID #: 6881
`
`
`
`
`
`BY THE COURT:
`
`/s/ Mitchell S. Goldberg
`MITCHELL S. GOLDBERG, J.
`
`2
`
`